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Abstract
Background: The autosomal dominant form of Emery-Dreifuss muscular dystrophy (AD-EDMD) is caused by
mutations in the gene encoding for the lamins A and C (LMNA). Lamins are intermediate filament proteins which
form the nuclear lamina underlying the inner nuclear membrane. We have studied the expression and the
localization of nuclear envelope proteins in three different cell types and muscle tissue of an AD-EDMD patient
carrying a point mutation R377H in the lamin A/C gene.
Results: Lymphoblastoid cells, skin fibroblasts, primary myoblasts and muscle thin sections were studied by
immunocytochemistry and electron microscopy. Cellular levels of A-type lamins were reduced compared to
control cells. In contrast, the amount of emerin and lamin B appeared unaltered. Cell synchronization experiments
showed that the reduction of the cellular level of A-type lamin was due to instability of lamin A. By electron
microscopy, we identified a proportion of nuclei with morphological alterations in lymphoblastoid cells, fibroblasts
and mature muscle fibres. Immunofluorescence microscopy showed that a major population of the lamin B
receptor (LBR), an inner nuclear membrane protein, was recovered in the cytoplasm in association with the ER.
In addition, the intranuclear organization of the active form of RNA polymerase II was markedly different in cells
of this AD-EDMD patient. This aberrant intranuclear distribution was specifically observed in muscle cells where
the pathology of EDMD predominates.
Conclusions: From our results we conclude: Firstly, that structural alterations of the nuclei which are found only
in a minor fraction of lymphoblastoid cells and mature muscle fibres are not sufficient to explain the clinical
pathology of EDMD; Secondly, that wild type lamin A is required not only for the retention of LBR in the inner
nuclear membrane but also for a correct localization of the transcriptionally active RNA pol II in muscle cells. We
speculate that a rearrangement of the internal chromatin could lead to muscle-specific disease symptoms by
interference with proper mRNA transcription.
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Background
The lamins are a group of intermediate filament proteins
which form major components of the nuclear lamina in
most differentiated eukaryotic cells. The expression of
lamins is developmentally regulated but most cell types in
the adult body contain A- and B-type lamins (for review
see [1]). In humans, three genes, LMNA, LMNB1 and
LMNB2, encode distinct subtypes of proteins. The LMNA
gene gives rise to lamins A and C by alternative splicing
[2]. Lamins B1 and B2 are encoded by the two LMNB
genes and are constitutively expressed independently of
developmental stage. The expression of lamin B3, a splice
variant of lamin B2, is limited to germ cells. In order to
build up the nuclear lamina, lamins form homo- and het-
eropolymers which associate with other proteins into a
network that underlies and supports the nuclear mem-
brane (for review see [3]).
The lamins came into the focus of clinical interest when
the LMNA gene was found to cause a rare heritable pro-
gressive myopathy, the autosomal-dominant form of
Emery-Dreifuss muscular dystrophy (AD-EDMD, OMIM
#181350; [4]). Another variant of this disease which is
transmitted as an X-linked trait (X-EDMD, OMIM #
310300), had been earlier associated to mutations in
emerin, a transmembrane protein of the inner nuclear
membrane [5]. Thus, EDMD was the first disease found to
be due to defects in proteins of the nuclear envelope. Clin-
ically, the two variants are quite similar and are character-
ised by (1) a progressive muscular weakness with humero-
peroneal distribution, (2) early contractures of the Achil-
les tendon, the elbows and the post-cervical muscles, and
(3) atrial arrhythmias and/or a cardiomyopathy. A combi-
nation of these three cardinal symptoms is rarely seen in
other myopathies and appears to be a discriminating fea-
ture of EDMD. Typically, symptoms develop in the second
decade of life with the contractures often preceding clini-
cally significant weakness. In young patients, the cardiac
arrhythmia may go unnoticed and can lead to sudden
death by cardiac arrest. Therefore, an early diagnosis is
potentially life saving, since heart function can be stabi-
lised by implantation of a cardiac pace maker [6].
In the past years, defects in the LMNA gene have been rec-
ognised to cause a pleiotropy of clinical phenotypes in 3
other autosomal dominant and 3 recessive disorders: (i) a
form of limb-girdle muscular dystrophy with cardiac con-
duction defects (LGMD1B, OMIM #159001; [7]); (ii) a
dilated cardiomyopathy with conduction defects
(CMD1A; OMIM #115200; [8]), (iii) a familial partial
lipodystrophy (FPLD; OMIM #151660; [9,10]); (iv) a
recessive form of EDMD [11], (v) an autosomal recessive
axonal neuropathy (Charcot-Marie-Tooth disease 2B1;
CMT2B1; OMIM #605588; [12,13]) and (vi) mandibu-
loacral dysplasia (MAD; OMIM #248370, [14]). Recently,
dominant de novo mutations have been shown to cause
the Hutchinson-Gilford progeria (HPGS; OMIM
#176670, [15,16]). Furthermore, an association of a
LMNA polymorphism to quantitative determinants of
obesity was reported [17]. A review of the published
mutations, mostly heterozygous amino acid replace-
ments, suggested that interactions of specific domains of
the lamin A/C protein with as yet unknown proteins may
lead to the spectrum of tissue-specific mutations
[11,18,19]. In the case of Emery-Dreifuss muscular dystro-
phy mutations are found mainly in the C-terminal
domain of the protein leading to disturbance of dimerisa-
tion and fusion of the dimers to filaments [17,20]. A
direct interaction between emerin and the lamins could
be shown [21,22]. Moreover, mutations in either one of
these proteins cause similar clinical symptoms indicating
a strong interaction within a common function.
Despite numerous observations, up to now there is no
conclusive explanation for the tissue-specific effect of the
mutations in the emerin-lamin A/C complex. Although
the proteins are expressed ubiquitously, mutations lead to
primary cell damage and pathology in very specific cell
types only whereas in most other tissues the mutations
show no effect.
Progressive muscle wasting in EDMD is the result of a fail-
ure of adequate muscle regeneration. Muscle fibres
destroyed by mechanical stress cannot be reconstituted by
a sufficient amount of newly differentiated myotubes.
This leads to a decrease of muscle mass and subsequent
weakness [23]. According to one hypothesis, the function
of the emerin-lamin A/C complex is the stabilisation of
the nuclear envelope [24]. This may be of particular
importance in cells which are subject to mechanical stress
like muscle cells [25]. The disturbance of this stabilizing
system and the resulting cell death in the affected muscle
could, thus, explain the clinical symptoms of the disease.
The mutations in the lamin A-gene which have been ana-
lysed in detail [26] show different, partly position
dependent effects like mislocalization of lamin A
(R453W) or lamin C (E358K), and an apparent reduction
of emerin expression in the nucleus (R527P; [26,27]).
This could compromise the structural stability of the
nucleus as a consequence of the altered lamina [28,29]. In
other mutations like L530P, a wild-type distribution of
lamin A, lamin C and emerin was observed [27]. These
results could indicate that in this case another so far
unknown function of lamin A and/or emerin is disturbed.
Recently a role of lamin A and associated proteins in gene
expression has been postulated [30]. Furthermore, cDNA
microarray analysis has revealed changes in gene expres-
sion in X-EDMD fibroblasts [31].BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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We had the rare opportunity to study three different cell
types from one AD-EDMD patient (99-3) carrying a point
mutation in the rod domain of the LMNA gene which
replaces arginine 377 by histidine (R377H). In the present
study we used lymphoblasts, myoblasts, skin fibroblasts
and muscle thin sections to examine the effects of this
mutation on nuclear structure and proteins. Our results
show that the mutation LMNA R377H causes defects in
lamin A stability and assembly which can extend to an
aberrant nuclear phenotype. We further demonstrate a
mislocalization of LBR and RNA pol II in the patient's
cells.
Results
The cellular level of the A-type lamins is reduced in cells of 
AD-EDMD patient 99-3
In the course of the diagnostic work-up, a Western blot of
proteins from lymphoblastoid cells of the patient 99-3
showed a normal expression of emerin. A mutation in the
emerin gene was excluded by subsequent sequencing
(data not shown). Screening of the LMNA gene revealed a
mutation in codon 377 (CGC > CAC) replacing Arg377 by
His (LMNA R377H).
In order to study the expression level of nuclear lamin in
this patient, we have separated nuclear proteins from dif-
ferent cell lines of controls and patient 99-3 by one-
dimensional SDS-PAGE and transferred them to nitrocel-
lulose (Fig. 1). In order to ensure that the lamin proteins
have been well solubilized, the different samples were
resuspended twice in the SDS-PAGE sample buffer. When
nuclear proteins of the control cells were probed with
antibodies against lamin A/C or B2 (lanes 1–3), the lamin
antibodies reacted in all samples. In contrast, we found
that in lymphoblastoid (lane 4) and fibroblast cells (lane
6) of the patient, the cellular level of lamin A/C was
reduced (compare lanes 4, 6 with lanes 1, 3). Surprisingly,
in myoblast cells (lane 5) and muscle tissue (lane 8) the
level of lamin A/C appeared normal. The emerin antibody
reacted in all nuclear extracts with a band of nearly uni-
form intensity indicating that equivalent amounts of pro-
tein had been loaded onto the different lanes (lanes 1–8).
The same blot was re-probed with anti-fibrillarin antibod-
ies to ensure equal protein loading (lanes 1–6 insert). We
further studied the three cell types by immunofluores-
cence microscopy. When lymphoblastoid cells with the
mutation LMNA R377H were labelled with the antibodies
against emerin (Fig. 2a) or lamin B2 (Fig. 2c), all nuclei
revealed the typical prominent staining of the nuclear
periphery. However, after incubation with the anti-lamin
A/C antibody, we found a deficiency of the immunostain-
ing in 90% of nuclei (5121 out of 5690, Fig. 2b), while
control lymphoblastoid cells showed clearly positive
immunostaining of the nuclear membrane with all anti-
bodies used (Fig. 2d,2e,2f). This result is in agreement
with the immunoblot data, where lymphoblastoid cells
showed a clear reduction of the lamin A/C signal.
In order to address potential tissue-specific effects of the
LMNA R377H mutation we studied lamin A/C levels in
other cell types from the same patient. Immunofluores-
cence studies of emerin, lamin A/C and lamin B on fibrob-
last cells revealed a pattern of intense staining at the
periphery of the cell nucleus after incubation with emerin
or lamin B antibodies (Fig. 3a,3c) as previously described
for the lymphoblastoid cells (Fig. 2a,2c). However, we
observed a difference in the staining of lamin A/C.
Whereas nearly all lymphoblastoid nuclei showed a
reduced or absent staining (Fig. 2b) only approximately
20% of the fibroblast nuclei (614 out of 3080) were not
labelled by the lamin A/C antibody (Fig. 3b). As expected,
the fluorescence of control fibroblasts showed an intense
staining of the nuclear envelope with all antibodies used
(Fig. 3d,3e,3f).
In the immunoblot experiments we had detected a
reduced amount of lamin A/C in lymphoblastoid and
fibroblast cells but surprisingly not in myoblasts and
mature muscle (see Fig. 1). However, by immunofluores-
cence microscopy of myoblasts (Fig. 4) or frozen sections
of a muscle biopsy of patient 99-3 (Fig. 5), about 5% (169
out of 3290) of myoblast nuclei (Fig. 4b) and 5% (79 out
of 1580) of mature muscle nuclei showed only a faint
staining with lamin A/C antibodies (Fig. 5b, arrow). In
contrast, we never saw a reduction of lamin A/C staining
in control myoblasts (3430 nuclei) or mature muscle
(1650 nuclei). Nuclear periphery staining with emerin or
lamin B2 antibodies was normal (Figs. 4, 5a,5c) as was the
staining of control myoblasts and muscle sections by all
antibodies (Figs. 4, 5d,5e,5f). It is interesting to note that
the reduced amount of lamin A/C has been observed not
only in cultured cells (Figs. 2, 3, 4), but also on frozen
muscle sections (Fig. 5). This indicates that the observed
reduction of lamin A/C staining is not caused by our cell
culture conditions. Given that only 5% of nuclei in myob-
lasts and mature muscle fibres showed a reduction of
lamin A/C staining it is not surprising that immunoblot-
ting failed to demonstrate a reduction of the level of lamin
A/C by (Fig. 1, lane 5).
These results support the interpretation that the cellular
level of lamin A/C is reduced in cells carrying a R377H
mutation in the LMNA gene. For the first time, the reduc-
tion of lamin A/C could be demonstrated by two inde-
pendent methods, i.e. Western blotting and
immunofluorescence microscopy. Nuclear alterations in
muscle cells of an AD-EDMD have been described before
[32], however, the immunohistochemical reactions with
anti-lamin A/C antibodies were normal in this study.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
Page 4 of 16
(page number not for citation purposes)
A-type lamins are reduced in cells with the mutation LMNA R377H Figure 1
A-type lamins are reduced in cells with the mutation LMNA R377H. To determine the level of lamin A/C, lamin B 
and emerin in AD-EDMD patient 99-3, whole proteins of cell extracts from patient lymphoblastoid (lane 4), myoblast (lane 5), 
fibroblast (lane 6) cultures and mature muscle (lane 8) or control lymphoblastoid (lane1), myoblast (lane 2) fibroblast (lane 3) 
cultures and mature muscle (lane 7) were separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with mab 
R27 to detect lamin A/C, mab X223 to detect lamin B2, mab NCL-emerin to detect emerin and PEG3 to detect fibrillarin. The 
same nitrocellulose was used for all antibodies. The antibodies were stripped before the incubation with the next one. The 
level of lamin A is reduced in lymphoblastoids and fibroblasts cells (see arrows in lanes 4 and 6). Molecular mass standards are 
indicated in kDa.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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In total, we have screened lymphoblastoid cells from
another 14 patients clinically diagnosed with AD-EDMD,
but we detected reduced levels of lamin A/C only in
patient 99-3 and one other patient with an as yet unchar-
acterized genetic defect (data not shown).
A-type lamin is unstable in cells with the mutation LMNA 
R377H
In order to study the stability of the mutated lamin A/C,
lymphoblastoid cells of patient 99-3 were blocked in the
G1 phase by incubation in medium with 10 µM lovastatin
[33]. The arrest in the G1 phase was checked by FACS
analysis (data not shown). After G1 phase arrest it is pos-
sible to analyze the stability of proteins during a defined
time period. The level of lamin A/C expression in G1-
arrested patient cells was assayed on immunoblots and
compared to G1 arrested control cells. In control cells, the
level of lamin A/C was stable in the presence of lovastatin
over an incubation period of up to 48 h. (Fig. 6A, lanes 1–
3). In patient cells, the amount of lamin A was considera-
bly reduced by incubation with lovastatin (Fig. 6A, lanes
4–6) while the amounts of lamin C and emerin appeared
only slightly reduced. This reduction is not due to an inhi-
bition of processing [34]. If so, our antibody would also
recognize the pre-lamin A. Similar results were obtained
after incubation with the protein synthesis inhibitor
cycloheximide (50 µg/ml). The amount of lamin A and C
was clearly reduced in the patient sample (compare Fig.
6B lanes 3 and 4). These data, in combination with the
observation of the reduced levels of lamin A by immuno-
blotting and immunofluorescence microscopy support
the hypothesis that the mutation R377H leads to a shorter
half life of lamin A.
Immunostaining for lamin A/C is deficient in lymphoblastoid  cells with mutation LMNA R377H Figure 2
Immunostaining for lamin A/C is deficient in lym-
phoblastoid cells with mutation LMNA R377H. Indi-
rect immunofluorescence microscopy of lymphoblastoid cells 
from patient cells (a-c) and control cells (d-f) after staining 
with antibodies against emerin (a,d), lamin A/C (b,e) and 
lamin B (c,f). Lamin A/C staining is less intense in patient cells 
(b) compared with the control (e). The corresponding 
Hoechst fluorescence in shown (a'-c' and d'-f'). Bar: 10 µm. Some fibroblast cell nuclei from the AD-EDMD patient 99-3  are negative for antibodies to lamin A/C Figure 3
Some fibroblast cell nuclei from the AD-EDMD 
patient 99-3 are negative for antibodies to lamin A/C. 
Immunolabelling of fibroblast cells with mutation LMNA 
R377H (a-c) and control cells (d-f) was done by using anti-
bodies against emerin (a,d), lamin A/C (b,e) and lamin B (c,f). 
Not all nuclei stain for lamin A/C in patient cells (compare b 
with e). The corresponding phase-contrast images (a"-c"; d"-
f") and Hoechst fluorescence (a'-c'; d'-f') are shown. Bars 
(c",f") 10 µm.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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Nuclear alterations in cells of the AD-EDMD patient 99-3
It has been previously described that about 10% of muscle
cell nuclei from AD-EDMD patients show an alteration of
nuclear morphology [32,35]. To examine their ultrastruc-
ture more closely, nuclei of lymphoblastoid cells (875),
fibroblasts (520), myoblasts (490), and mature muscle
fibres (375) from patient 99-3 and controls were analysed
by electron microscopy. In lymphoblastoid cells with the
mutation LMNA R377H, a striking alteration of nuclear
morphology was observed. While the nuclei of control
lymphoblastoid cells display a normal morphology (Fig.
7a,7a'), the nuclei of the patient cells were surrounded by
a continuous double membrane with numerous blebs
and the peripheral heterochromatin was no longer associ-
ated with the inner nuclear membrane (Fig. 7b, arrows).
Due to the chromatin condensation, the inner pore fibrils
became visible (Fig 7b', arrows). Such nuclear alterations
were found in about 40% of the patient's lymphoblastoid
cells. However, the cells proliferated normally indicating
that the observed morphological changes are not indica-
tive of apoptosis.
In fibroblasts (Fig. 7d,7d'), myoblasts (data not shown)
and muscle sections (Fig. 7f,7f') some nuclei showed
nuclear membrane invaginations (Fig. 7d',7f'), while the
Some myoblasts cell nuclei from the AD-EDMD patient 99-3  are negative for antibodies to lamin A/C Figure 4
Some myoblasts cell nuclei from the AD-EDMD 
patient 99-3 are negative for antibodies to lamin A/C. 
Immunolabelling of myoblasts cells with mutation LMNA 
R377H (a-c) and control cells (d-f) was done by using anti-
bodies against emerin (a,d), lamin A/C (b,e) and lamin B (c,f). 
Not all nuclei stain for lamin A/C in patient cells (compare b 
with e). The corresponding phase-contrast images (a"-c"; d"-
f") and Hoechst fluorescences (a'-c'; d'-f') are shown. Bars 
(c",f") 10 µm.
Immunostaining for lamin A/C is deficient in frozen muscle  sections of the AD-EDMD patient 99-3 Figure 5
Immunostaining for lamin A/C is deficient in frozen 
muscle sections of the AD-EDMD patient 99-3. Immu-
nolabelling of frozen muscle sections from patient 99-3 (a-c) 
and control (d-f) was performed for emerin (a,d), lamin A/C 
(b,e) and lamin B (c,f). Lamin A/C staining is less intense in 
patient (arrow in b) compared with the control (e). The cor-
responding phase-contrast images (a"-c"; d"-f") and Hoechst 
fluorescences (a'-c'; d'-f') are shown. Bars (c",f") 10 µm.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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Stability profiles of lamin A/C and emerin in lymphoblastoid  cells culture after treatment with lovastatin or cycloheximide Figure 6
Stability profiles of lamin A/C and emerin in lym-
phoblastoid cells culture after treatment with lovas-
tatin or cycloheximide. To determine the stability profiles 
of lamin A/C and emerin, cells were grown in the presence 
or absence of lovastatin (panel A) or cycloheximide (panel B). 
In A, lymphoblastoid cells with the mutation LMNA R377H 
(lanes 4–6) and control (lanes 1–3) were grown in the pres-
ence of 10 µM lovastatin for 24 h (lanes 2, 5), for 48 h (lanes 
3, 6) or in the absence of lovastatin (lanes 1, 4). In B, lym-
phoblastoid cells with the mutation LMNA R377H (lane 4) 
and control (lane 2) were grown in the absence (lanes 1, 3) 
or presence of 50 µg/ml of cycloheximide (lanes 2, 4). Whole 
cell extracts were resolved on SDS-PAGE. Proteins were 
transferred to nitrocellulose and immunoblotted with the 
mab R27 to detect lamins A/C and with the mAb NCL-
emerin to detect emerin on the same stripped nitrocellulose. 
Significantly, lamin A from AD-EDMD patient is instable 
(compare panel A lanes 5, 6 with lanes 2, 3 and also panel B 
lane 4 with lane 2). Molecular mass standards are indicated in 
kDa.
Electron microscopic examination of the nuclear morphology  in AD-EDMD patient cells Figure 7
Electron microscopic examination of the nuclear 
morphology in AD-EDMD patient cells. Electron 
microscopic analysis of lymphoblastoids (a-b'), fibroblasts (c-
d') and frozen muscle sections (e-f') from AD-EDMD patient 
99-3 (b,b',d,d',f,f') and from control (a,a',c,c',e,e'). In the con-
trol a largely continuous layer of heterochromatin is in con-
tact with the inner face of the nuclear envelope [visible at 
low (a,c,e) and higher magnification (a',c',e')]. In the lymphob-
lastoid cells with mutation LMNA R377H the condensed 
peripheral heterochromatin appears clearly detached from 
the nuclear envelope (arrows in b), the double membrane 
surrounding the chromatin contains numerous blebs and the 
inner pore fibrils become visible as shown at higher magnifi-
cation (b', arrows). In patient fibroblast cells and muscle sec-
tions, nuclei showed nuclear membrane invaginations while 
the morphology of the membrane and nuclear pores was not 
disturbed as shown at higher magnification (d',f', arrows). In 
patient mature muscle cells, condensation of the peripheral 
chromatin was observed (f) compared to control (e). Bars (a-
f): 2 µm; (a'-f') 0.2 µm.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
Page 8 of 16
(page number not for citation purposes)
morphology of the membrane and the nuclear pores was
not disturbed (Fig. 7d',7f' arrows). Such invaginations
were found in 10% of nuclei studied, but never observed
in control cells (Fig. 7c',7e'). These membrane invagina-
tions seem to be different from both the large intranuclear
channel system previously reported for muscle nuclei of
X-EDMD patients and the deep invaginations of the
nuclear membrane observed in an AD-EDMD patient
[35]. In muscle sections, the peripheral chromatin
appeared more condensed compared to controls (com-
pare Fig. 7e and 7f). This chromatin condensation was
found in 20% of the nuclei studied.
Distribution of LBR in different cell types from patient 99-
3
Since a selective retention is required for the localization
of integral proteins in the inner nuclear membrane [36-
38], it is possible that A-type lamins are involved in this
process. Therefore, we have studied the distribution of
several inner nuclear membrane proteins in different cell
types from patient 99-3 and in control cells by immuno-
cytochemistry. Emerin (Figs. 2a, 3a, 4a, 5a and 2d, 3d, 4d,
5d), LAP2β (data not shown; [39,40]), and MAN1 (data
not shown; [41]) showed a normal localization at the
nuclear rim in all cell types. The presence of emerin in the
nuclear envelope indicates that the interaction of emerin
with the lamina is not directly affected by the mutation
LMNA R377H, localized in the rod domain, as has been
previously shown [26]. Surprisingly, immunofluores-
cence microscopy revealed differences in the subcellular
localization of the lamin B receptor. LBR possesses 8
membrane spanning domains and is a potential binding
partner for nuclear ligands like lamin B, human chromo-
domain protein HP1, and DNA (see review [42]). In con-
trol fibroblasts and myoblasts, LBR is highly enriched at
the nuclear envelope (Fig. 8a',8c'). The same holds true for
lymphoblastoid cells (data not shown). In about 95% of
patient cells (2560 fibroblasts, 2840 myoblasts and 4326
lymphoblastoids), a large fraction of LBR immunostain-
ing is found in the cytoplasm with a distribution similar
to ER proteins (Fig. 8b',8d'). This was verified by double
immunofluorescence using ribophorin II antibodies (data
not shown). After double labelling with anti lamin A/C
and anti LBR in patient fibroblasts and myoblasts (Fig.
8e",8f") we could show that the absence of lamin A/C cor-
relates with the location of LBR to the ER (Fig. 8e,8e").
However, due to the fact that in 95% of patient cells (see
above) a large fraction of LBR was found in the cytoplasm
but that a lamin A/C deficiency was observed only in 5 to
20% of nuclei (myoblasts and fibroblasts, respectively),
our data suggest that not the absence but the structural
changes in the mutated lamin are inducing the
anomalous location of LBR. While the overall levels of
LBR in patient and control cells were identical when com-
pared by immunoblotting with anti LBR antibodies (data
not shown), a considerable amount of LBR is no longer
retained within the inner nuclear membrane, but
probably diffuses to the ER via the membrane continuities
at the periphery of the nuclear pore complexes [43]. How-
ever, lamin B2 still concentrates within the nuclear enve-
lope (Fig. 8 compare a,c with b,d). These results indicate
that the mislocalization of LBR correlates with the expres-
sion of the mutated lamin A.
Differences in RNA pol II localization in myoblast cells 
with the mutation LMNA R377H
It has been reported that lamins and lamin-associated
proteins bind to chromatin and that the disruption of
nuclear lamin polymers inhibits RNA pol II-dependent
transcription [30]. Since our data indicated that the LMNA
R377H mutation impairs lamina stability we examined
the distribution of phosphorylated RNA pol II in our
patients and control cells. Immunofluorescence with RNA
pol II antibodies revealed a normal, characteristic pattern
of nuclear speckles not only in control fibroblasts (Fig.
9a") and myoblasts (Fig. 10a") (2970 and 2765 cells
observed respectively) but also in fibroblast cells of
patient 99-3 (Fig. 9b") (3240 cells observed). However,
the distribution of phosphorylated RNA pol II was altered
in 75% (1981 of 2643) of myoblasts with the mutation
LMNA R377H and appeared to concentrate at the poles of
the nuclei (Fig. 10b",10c", arrows). After double labelling
of patient myoblasts with anti lamin A/C and anti RNA
pol II (V/22) we could show that the absence or reduction
of lamin A/C correlates with the altered distribution of
phosphorylated RNA pol II (Fig. 10e,10e"). Similar to the
results with LBR (see above), the dramatic alteration of
RNA pol II distribution observed in 75% of the myoblasts
compared to the reduced level of lamin A/C observed in
only 5% of myoblasts suggests that the relocalization of
RNA pol II within nuclei of muscle cells is a direct or indi-
rect consequence of not only the absence but also of struc-
tural changes in lamin A. Furthermore, the lamin A
mutant R377H seems to influence exclusively the localiza-
tion of the phosphorylated form of RNA pol II, since the
distribution of the unphosphorylated, inactive form of
RNA pol II was identical to that in controls (Fig. 10d",
compare to a").
Discussion
LMNA R377H induces abnormalities in the nuclear 
envelope
In this study, we describe the effects of a defective nuclear
lamin A in cells derived from AD-EDMD patient 99-3.
Genomic sequencing of all the LMNA gene's exons identi-
fied a mutation in exon 6, replacing arginine 377 by histi-
dine. The R377H mutation has been reported before in a
family with limb girdle muscular dystrophy 1B [7]. Like a
number of other mutations it is localized in the helical
rod region. By Western blotting and immunofluorescenceBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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Mislocalization of LBR in cells with mutation LMNA R377H Figure 8
Mislocalization of LBR in cells with mutation LMNA R377H. Fibroblasts (a,b,e) and myoblasts (c,d,f) from control (a,c) 
or patient (b,d,e,f) were double labelled with a mAb directed against lamin B2 (a-d) or lamin A/C (e,f) and with guinea pig anti-
bodies recognizing LBR (a'-f') and then analyzed by confocal microscopy. Note the colocalization of lamin B and LBR at the 
nuclear envelope in control cells (a",c"). In contrast, in patient cells LBR shows also a cytoplasmic localization (b",d",e",f"). 
Merged pictures are shown in a"-f". The contour of the nucleus is marked by a white line (e"). Bar: 15 µm.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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microscopy, it was possible to demonstrate for the first
time that this mutation leads to a reduction of the A-type
lamin level. A less intensive staining for lamin A/C had
already been reported after immunolabelling of frozen
muscle and heart sections of AD-EDMD patients [24,44]
as well as in cultured skin cells of an X-EDMD patient
[45]. But until now no reduction of A-type lamin was
observed by protein analysis using Western blotting. The
reduction of the total lamin A level is indicative of this
mutation rendering lamin A less stable. In a dominant dis-
ease, 50% of normal lamin A/C may be expected from the
wildtype allele while the affected allele may produce
another 50% of an altered protein. Our results suggest
that mutated lamin A/C is unstable and rapidly degraded.
During G1 phase arrest induced by the drug lovastatin or
after protein synthesis inhibition by cycloheximide, the
amount of A-type lamin in cells with the mutation R377H
was decreased compared to control cells. Previous studies
have reported an increased solubility of lamins in skin
fibroblasts from an X-EDMD patient [46]. In a recent
report Vigouroux and co-workers [47] showed that a
LMNA R482Q/W mutation in fibroblasts from lipodys-
trophic patients does not affect the nuclear content in
lamins, but increases their extractability. On the other
hand Östlund et al. [48] showed, after pulse-chase analy-
sis, that several other lamin A mutants were as stable as
wild-type lamin A. The difference between our findings
and those reported by Markiewicz et al. [46], Vigouroux et
al. [47] and Östlund et al [48] could rather reflect the
effect of different lamin mutations than differences
between AD-EDMD and X-EDMD or lipodystrophy. All
lamins, i.e. B1, B2, A and C form dimers that assemble
into multimeric filaments to form the nuclear lamina (see
review [3]). For this process a functional rod domain is
necessary [49]. The point mutation R377H is localized in
the rod domain and could specifically change the 3D
structure of the lamin A, disrupt intermolecular interac-
tions involved in the normal dimerisation process, and
thus affect the stability of the lamin network.
Previous histological and histochemical studies described
dystrophic features in muscles from an AD-EDMD patient
[44,35]. In this study, we found that the LMNA R377H
mutation has an impact not only on lamin A stability but
Normal distribution of the phosphorylated RNA pol II in fibroblast nuclei of AD-EDMD patient 99-3 Figure 9
Normal distribution of the phosphorylated RNA pol II in fibroblast nuclei of AD-EDMD patient 99-3. Fibroblast 
culture cells from control (a) or patient (b) were immunolabelled with mab V/22 recognizing RNA pol II (a",b"). Note the nor-
mal distribution of RNA pol II all over the nucleus in control as well as in patient fibroblasts (compare a" and b"). The corre-
sponding phase-contrast images (a,b) and Hoechst fluorescences (a',b') are shown. Bar: 10 µm.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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Uneven distribution of the phosphorylated RNA pol II in myoblast nuclei from AD-EDMD patient 99-3 Figure 10
Uneven distribution of the phosphorylated RNA pol II in myoblast nuclei from AD-EDMD patient 99-3. Myob-
last culture cells from control (a)or patient (b-e") were immunolabelled with mab V/22 recognizing the phosphorylated RNA 
pol II (a"-c") or with 8WG16 recognizing the unphosphorylated RNA pol II (d"). The patients myoblasts were double labelled 
with a polyclonal anti-lamin A/C antibody (e) and V/22 (e') and then analyzed by confocal microscopy. The merged picture is 
shown in (e"). Note that the dramatic concentration of phosphorylated RNA pol II is observed at the poles of the nuclei in 
patient cells (b",c",e" arrows). Note the normal localization of the phosphorylated RNA pol II in control cells (compare a" with 
b",c" and e") and of the unphosphorylated RNA pol II (d"). The corresponding phase-contrast images (a-d) and Hoechst fluo-
rescences (a'-d') are shown. Bars: 10 µm.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
Page 12 of 16
(page number not for citation purposes)
also on nuclear architecture. In patient lymphoblastoid
cells, the nuclei showed a condensation of peripheral het-
erochromatin. In addition, we observed a damaged
nuclear membrane with numerous blebs. Abnormal
nuclear morphology of muscle and skin cells were previ-
ously observed not only in X-EDMD patients [45,50] but
also in an AD-EDMD patient [32]. It is interesting to note
that damage of nuclear membranes with numerous blebs
were only observed in cells of X-EDMD patients [45,50].
However, similar ultrastructural abnormalities have been
described in fibroblasts and hepatocytes from mice lack-
ing A-type lamins [51]. Structural abnormalities were also
seen in about 10 to 20% of our patient's muscle and
fibroblast nuclei. However, the nuclear membrane inclu-
sions as well as the peripheral chromatin condensation
observed in our AD-EDMD patient were different from
the deep invaginations of the nuclear envelope producing
pseudoinclusions reported by the group of Fidzianska
who also observed strong alterations in chromatin
organization in an AD-EDMD patient with a LMNA
R453W mutation [35]. Taken together, both studies sug-
gest that different mutations in LMNA may cause different
morphological abnormalities in nuclei. It is tempting to
correlate this to the wide spectrum of clinical phenotypes
associated with LMNA gene mutations [52].
The abnormality of the nuclear envelope in mutated
myoblasts was also reflected by the different permeabili-
zation conditions required for the immunolabelling of
control and patient myoblasts. A staining of the nuclei
and nuclear envelope from patient myoblasts was
obtained when cells were permeabilized for only 2 min in
-20°C methanol:aceton (1:1). In contrast, control myob-
lasts required at least 20 min of permeabilization. This
observation indicates that the nuclear envelope of the
patient's cells is more permissive for antibodies probably
due to reduced stability of the lamina. Indeed, it has been
previously described that an intact lamina is essential for
the correct and stable reassembly of membrane vesicles in
forming a nuclear envelope [28,29].
From published reports [32,35,45] and our own observa-
tions it appears that the observed nuclear alterations affect
a minority of nuclei and are not tissue specific. It is, there-
fore, hard to conceive that the structural changes alone
can cause the pathology of LMNA defects. In the case of
our patient this nuclear alteration is probably due to a
reduced stability of A-type lamin. In our previous work,
we were able to demonstrate that an intact lamina is
essential for the correct and stable reassembly of an intact
nuclear double membrane around the daughter nuclei
after mitosis [28,29].
Other authors have demonstrated that emerin is strongly
associated with the nuclear lamina [53,54] and the data of
Vaughan et al. [27], Harborth et al. [55], Östlund et al.
[48] and Raharjo et al. [56] suggest that lamin A is essen-
tial for anchorage of emerin to the inner nuclear mem-
brane. A direct interaction between recombinant emerin
and lamin A has been shown in vitro [21]. However, it was
also reported that an altered lamin distribution can occur
without relocalization of emerin in FPLD fibroblasts car-
rying R482Q, R482W or R482L mutations [47,57]. In
accordance with these data, emerin appeared correctly
localized in the nuclear membrane in cells with the LMNA
R377H mutation as shown by our immunolabelling
experiments. In none of our experiments did the LMNA
R377H mutation have an apparent influence on emerin.
In summary, the data suggest that different amino acid
substitutions elicit different effects on the intermolecular
interactions of A-type lamins and that their cellular level
does not play a central role in retention of emerin in the
nuclear membrane. Probably only a small amount of
lamin A is required to immobilize emerin into the nuclear
envelope. Indeed, Harborth et al. [55] were able to
demonstrate that after lamin A/C silencing, emerin re-dis-
tributed to the cytoplasm.
Evidence for influences of LMNA R377H on chromatin 
organization
A set of integral nuclear proteins is known to interact with
the lamina. Thus, the retention of these proteins at the
inner nuclear membrane could be mediated by their bind-
ing to lamins (for review see [58]). For example, the lamin
B receptor (LBR) and the lamina associated protein 2β
(LAP2β) interact more specifically with B-type lamins
[40,59], whereas emerin preferentially binds to A-type
lamins [21,22,51]. In this study, we present evidence for a
marked change of LBR localization in cells with the LMNA
R377H mutation. In control cells, LBR is concentrated
within the nuclear envelope, whereas in LMNA R377H
cells there is a partial loss of nuclear envelope associated
LBR, with a more general cytoplasmic distribution identi-
cal to that observed for ER proteins. Presumably LBR is no
longer retained in the inner nuclear membrane and dif-
fuses into the interconnected ER membrane system [37].
These results indicate that, at least in the cells with a
LMNA R377H mutation, correct LBR localization is con-
tingent upon the level of wild-type lamin A expression.
However, it has been shown that treatment of HL-60 cells
with retinoic acid decreased lamin A/C to negligible
amounts but LBR was still localized in the inner nuclear
membrane [60]. In Xenopus oocytes, peripheral chromatin
but no lamin is required for the retention of LBR in the
inner nuclear membrane [61]. Indeed, the nucleoplasmic
domain of LBR binds not only to B-type lamins [62,63]
but also to DNA [62] and chromosome/chromatin
domains [64,65] besides interacting with human chromo-
domain proteins [66,67]. Our data support the hypothe-BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
Page 13 of 16
(page number not for citation purposes)
sis that probably an as yet unknown chromatin protein
associated to A-type lamin is involved in the retention of
LBR in the nuclear envelope, and that in cells containing
the probably dominant LMNA R377H mutation, this
peripheral chromatin protein is no longer able to bind to
the mutated A-type lamin and thus fails to establish the
interaction with LBR.
Several roles have been proposed for the lamins, e.g. in
nuclear envelope assembly, nuclear architecture, mainte-
nance of chromatin organisation and DNA replication
[28,29,68-70]. The implication of lamins being involved
in the transcription process arose from the observation
that in cells with a disrupted lamin organization, RNA
polymerase II dependent transcription is dramatically
impaired [30,57]. It has also been suggested that lamin A
might affect gene expression by influencing the spatial
organization of chromatin [71,72]. Our results support
such data by demonstrating an abnormal accumulation of
the phosphorylated form of RNA polymerase II which
concentrates at the poles of the nuclei in myoblasts con-
taining the LMNA R377H mutation, correlating with the
failure of lamin A/C to assemble correctly.
An abnormal cytoplasmic accumulation of the RNA pol II
largest subunit has been previously described in sporadic
inclusion-body myositis, a progressive degenerative mus-
cle disease of older age [73]. In our study, we present the
first evidence for a marked difference in intranuclear
organization of the phosphorylated RNA polymerase II in
cells from an AD-EDMD patient. The disorganization was
specifically observed in muscle cells where the pathology
of EDMD predominates and where we also found nuclear
membrane inclusions. This observed nuclear change is in
accord with the nuclear chromatin reorganization
described in AD-EDMD by Fidzianska et al. [35].
Conclusions
We speculate that the rearrangement of internal chroma-
tin, provoked by mutant lamins, could lead to muscle-
specific disease symptoms by interference with proper
mRNA transcription. Indeed, transcription requires the
hyper-phosphorylated form of RNA pol II [74]. In this
context, an important observation was made by Tsu-
hakara et al. [31] who reported an altered gene expression
profile after cDNA microarray analysis of X-EDMD fibrob-
last cells lacking emerin. Thus, evidence is accumulating
that the peripheral lamina is not only important for main-
taining nuclear integrity but may also play a role in the
arrangement of chromatin for proper gene expression.
Perhaps this function of the lamina may hold the key to




The diagnosis of the AD-EDMD affected patient 99-3 was
based on clinical findings and DNA analysis. A specific
mutation in the lamin A gene was identified by direct
sequencing (LMNA c.1130G>A, R377H). For a histologi-
cal diagnosis, a muscle biopsy was taken from the vastus
lateralis [75]. In accordance with the ethical regulations of
the hospital, the patient gave informed consent for further
studies on his tissues. Lymphoblastoid and skin fibroblast
cells (SV80 fibroblasts for control) were cultured in
DMEM (Dulbecco's Modified Minimum Essential
Medium) with 10% FCS and 1% L-glutamine. Myoblasts
were cultured in DMEM high glucose with 20% FCS and
1% L-glutamine. Cells were grown at 37°C in a 5% CO2
incubator. Purity of myoblast cell cultures we checked by
Western blot analysis with anti-desmin antibodies as a
myogenic marker (data not shown).
For some experiments, the lymphoblastoid cells were
incubated for 24 h and 48 h in the presence of 10 µM lov-
astatin (Sigma, Taufkirchen, Germany). Under this
condition, the cells are arrested in the G1 phase [33]. In
order to initiate the cell cycle again, medium containing
lovastatin was removed and the cells were then incubated
in a medium containing 2 mM mevalonic acid. For inhi-
bition of protein synthesis, lymphoblastoid cells were
incubated for 24 h in the presence of 50 µg/ml cyclohex-
imide (Sigma). After the time of incubation the cells were
washed in medium without cycloheximide. Cells were
then processed for gel electrophoresis and
immunoblotting.
Antibodies
Ascites fluids of the following primary monoclonal anti-
bodies were used: X223 specific for the vertebrate B-type
lamin B2 [76], R27 against human lamin A and C [77], V/
22 directed against the phosphorylated CTD region of
RNA polymerase II (RNA pol II) which is located within
the C-terminal domain of the large subunit of RNA pol II
and required for the elongation process [78] (produced in
our lab) and 8WG16 which binds specifically to the CTD
heptapeptide repeat when this sequence is
unphosphorylated [79]. Mouse monoclonal antibodies
against emerin (NCL-emerin) were purchased from
medac-(Hamburg, Germany), anti desmin MA were pur-
chased from Sigma. The monoclonal antibody P2G3 was
used to detect fibrillarin [80]. Antibodies against the fol-
lowing antigens were used: Lamin B Receptor (LBR,
guinea pig; [81]); lamin A/C (N-18, goat, were purchased
from Santa Cruz Biotechnology, Santa Cruz, USA); Ribo-
phorin II as an endoplasmic reticulum (ER) protein
marker (rabbit; provided by Dr. B. Dobberstein).BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/12
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Immunofluorescence microscopy
Cultured cells grown on coverslips were fixed for 10 min
in -20°C methanol, transferred for 4 min to -20°C ace-
tone and air dried. Alternatively, the cells were fixed with
methanol:acetone 1:1 for 2 min at room temperature and
incubated immediately with primary antibodies. Control
cell culture of muscle cells were fixed for 20 min in -20°C
methanol:acetone 1:1 just before incubation with the pri-
mary antibodies. Pieces of muscle were shock frozen in
isopentane cooled with liquid nitrogen. 5 µm thin cryo-
sections of muscle were fixed with -20°C acetone for 10
min and air dried.
Fixed cells and cryo-sections were incubated with the pri-
mary antibodies for 30 min at room temperature. Anti-
lamin B and anti-emerin antibodies were diluted 1:200 in
PBS; anti-LBR, anti RNA pol II and anti-ribophorin anti-
bodies were respectively diluted 1:800, 1:300 and 1:500
in PBS. R27 monoclonal and N-18 polyclonal antibodies,
both directed against lamin A/C were used undiluted and
diluted 1:100 in PBS respectively. After washing with PBS
the samples were incubated for another 30 min with the
appropriate secondary antibody conjugated to Texas Red
or FITC (Dianova, Hamburg, Germany diluted 1:75 in
PBS). The samples were then counterstained with the
DNA-specific fluorescent dye Hoechst 33258 (5 µg/ml),
washed in PBS, air dried from ethanol and mounted in
Mowiol (Hoechst, Frankfurt, Germany).
Photographs were taken with a Zeiss Axiophot equipped
with epifluorescence optics and the appropriate filter sets
(Carl Zeiss, Oberkochen, Germany). Alternatively, photos
were taken with a CCD Pixel Fly camera (Klughammer,
Markt Indersdorf, Germany) or samples were viewed with
a Leica confocal microscope (Leica Lasertechnik GmbH,
Heidelberg, Germany).
Electron microscopy
Cells and muscle were fixed, embedded in Epon and proc-
essed for electron microscopy according to standard pro-
cedures (for details see [82]).
Gel electrophoresis and immunoblotting
Proteins were resolved on 12% SDS-PAGE [83]. For
immunoblots, proteins were electrophoretically trans-
ferred to nitrocellulose [84]. The membrane was blocked
with 10% non-fat dry milk in TBST (10 mM Tris-HCl, pH
= 8, 0,15 M NaCl, 0,05% Tween-20) followed by anti-
body-incubation at room temperature for 1 hour with
anti-emerin antibodies, or anti-fibrillarin antibodies, or
anti-desmin antibodies or anti-LBR antibodies (diluted
respectively 1:1000, 1:500 and 1:400 in the blocking
solution). After several washes with TBST the nitrocellu-
lose was incubated with the secondary peroxidase-cou-
pled anti-mouse or anti-guinea pig antibodies (Dianova,
Hamburg, Germany) at a dilution of 1:10.000 in TBST
with 10% dry milk followed for 1 hour at room tempera-
ture. The blots were washed again and bound antibodies
were visualized using the enhanced chemical lumines-
cence detection system (ECL; Amersham Buchler, Braun-
schweig, Germany).
For some experiments the nitrocellulose was stripped of
bound antibodies and reprobed as described in the man-
ufacturers protocol (Amersham Pharmacia Biotech) with
X223 (1:1000 in TBST, 1 hour incubation) R27 (undi-
luted, 2 hours incubation) and P2G3 (1:500 in TBST, 1
hour incubation).
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